Fecal Calprotectin Levels Predict the Clinical Course in Patients With New Onset of Ulcerative Colitis

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2013-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MIB.0b013e31827e78bePMID 23377170
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Results from the 2nd Scientific Workshop of the ECCO. I: Impact of mucosal healing on the course of inflammatory bowel disease.

  2011cited by this paper
• Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.

  2011cited by this paper
• Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis.

  2011cited by this paper
• Fecal calprotectin is a predictive marker of relapse in Crohn's disease involving the colon: a prospective study

  2010cited by this paper
• Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

  2010cited by this paper
• Infliximab, azathioprine, or combination therapy for Crohn's disease.

  2010cited by this paper
• Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse

  2009cited by this paper
• Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study)

  2009cited by this paper
• Ulcerative colitis: Correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C‐reactive protein, and blood leukocytes

  2009cited by this paper
• Can Calprotectin Predict Relapse Risk in Inflammatory Bowel Disease?

  2008cited by this paper
• Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.

  2007cited by this paper
• Ulcerative Colitis: Patient Characteristics May Predict 10-Yr Disease Recurrence in a European-Wide Population-Based Cohort

  2007cited by this paper
• Ulcerative colitis and clinical course: Results of a 5‐year population‐based follow‐up study (the IBSEN study)

  2006cited by this paper
• The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

  2006cited by this paper
• Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease

  2005cited by this paper
• Normalization of faecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease

  2004cited by this paper
• The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study.

  2001cited by this paper
• Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease.

  2000cited by this paper
• Course of ulcerative colitis: analysis of changes in disease activity over years.

  1994cited by this paper
• Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.

  1987cited by this paper

• Prudence is never excessive: Caution warranted in 5-aminosalicylic acid derivatives withdrawal for ulcerative colitis

  2025cites this paper
• The Latest Progress in Evaluating the Severity and Prognosis of Inflammatory Bowel Disease

  2023cites this paper
• Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms

  2023cites this paper
• Predictors of symptom trajectory in newly diagnosed ulcerative colitis: a 3-year follow-up cohort study

  2023cites this paper
• S100A9 is indispensable for survival of pneumococcal pneumonia in mice

  2023cites this paper
• Diagnostic Accuracy of Fecal Calprotectin for Predicting Relapse in Inflammatory Bowel Disease: A Meta-Analysis

  2023cites this paper
• Endoscopy for assessment of mucosal healing in ulcerative colitis: time bound or response guided?

  2022cites this paper
• Improved comprehensive evaluation of Crohn's disease activity by intestinal computed tomography enterography combined with endoscopy and biochemical indicators.

  2022cites this paper
• Usefulness of the Optimal Cutoff Value and Delta Value of Leucine-Rich Alpha 2 Glycoprotein in Ulcerative Colitis

  2022cites this paper
• Fecal microbiota dynamics during disease activity and remission in newly diagnosed and established ulcerative colitis

  2021cites this paper
• The Effect of Cretan High Phenolic Olive Oil on Fecal CalprotectinLevels in the Course of Multiple Sclerosis

  2020cites this paper
• Global Studies of Using Fecal Biomarkers in Predicting Relapse in Inflammatory Bowel Disease

  2020cites this paper
• The association among enterobacterial flora, dietary factors, and prognosis in patients with ulcerative colitis.

  2020cites this paper
• Approaches to Integrating Biomarkers into Clinical Trials and Care Pathways as Targets for Treatment of Inflammatory Bowel Diseases.

  2019cites this paper
• Clinical implications of fecal calprotectin and fecal immunochemical test on mucosal status in patients with ulcerative colitis

  2019cites this paper
• Predictors of mucosal healing during induction therapy in patients with acute moderate‐to‐severe ulcerative colitis

  2019cites this paper
• Fecal Eosinophil Cationic Protein Is a Diagnostic and Predictive Biomarker in Young Adults with Inflammatory Bowel Disease

  2019cites this paper
• Prediction of treatment outcome and relapse in inflammatory bowel disease

  2019cites this paper
• Ulcerative Colitis and Crohn's Disease Have the Same Burden and Goals for Treatment.

  2019cites this paper
• Role of image-enhanced endoscopy in the assessment of inflammatory bowel disease.

  2018influential citation
• From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

  2018cites this paper
• Monitoring Crohn’s disease activity: endoscopy, fecal markers and computed tomography enterography

  2018cites this paper
• Simultaneous Measurements of Faecal Calprotectin and the Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Stratify Risk of Relapse

  2018cites this paper
• Fecal immunochemical test for predicting mucosal healing in ulcerative colitis patients: A systematic review and meta‐analysis

  2018cites this paper
• The usefulness of fecal calprotectin in assessing inflammatory bowel disease activity

  2018cites this paper
• Assessing the Correlation of Fecal Calprotectin and the Clinical Disease Activity Index in Patients With Ulcerative Colitis

  2018cites this paper
• Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care—An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition

  2018cites this paper
• Fecal calprotectin is a strong predictive marker of relapse in Chinese patients with Crohn’s disease: a two-year prospective study

  2017cites this paper
• Raised faecal calprotectin is associated with subsequent symptomatic relapse, in children and adolescents with inflammatory bowel disease in clinical remission

  2017cites this paper
• Fecal calprotectin in inflammatory bowel diseases: update and perspectives

  2017cites this paper
• Dietary and metabolomic determinants of relapse in ulcerative colitis patients: A pilot prospective cohort study

  2017cites this paper
• The Mucosal Antibacterial Response Profile and Fecal Microbiota Composition Are Linked to the Disease Course in Patients with Newly Diagnosed Ulcerative Colitis

  2017cites this paper
• Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan

  2017influential citation
• Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease

  2017cites this paper
• Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis

  2017cites this paper
• Outcomes of limited period of adalimumab treatment in moderate to severe Crohn's disease patients: Taiwan Society of Inflammatory Bowel Disease Study

  2017influential citation
• Interest of fecal calprotectine dosage in inflammatory bowel diseases, state of the art and perspectives.

  2016cites this paper
• Can faecal calprotectin predict relapse in inflammatory bowel disease: a mini review

  2016cites this paper
• Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn’s disease patients on maintenance treatment with adalimumab

  2016cites this paper
• Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions.

  2016cites this paper
• Consecutive Measurements by Faecal Immunochemical Test in Quiescent Ulcerative Colitis Patients Can Detect Clinical Relapse.

  2016cites this paper
• Autonomic nervous system function predicts the inflammatory response over three years in newly diagnosed ulcerative colitis patients

  2016cites this paper
• Gastrointestinal Symtoms and Fatigue in Patients with Quiescent Ulcerative Colitis

  2016cites this paper
• Studies on inflammatory bowel disease and functional gastrointestinal disorders in children and adults

  2016cites this paper
• Clinical assessment of inflammatory bowel disease activity: a critical overview

  2016cites this paper
• Fecal Calprotectin as Predictor of Relapse in Patients With Inflammatory Bowel Disease Under Maintenance Infliximab Therapy

  2016cites this paper
• Correlation Between Calprotectin and Modified Rutgeerts Score

  2016cites this paper
• Fecal calprotectin in diagnosis and clinical assessment of inflammatory bowel disease

  2015cites this paper
• Fecal pyruvate kinase is not suitable for discrimination between inflammatory bowel disease exacerbation and acute gastroenteritis.

  2015cites this paper
• Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis

  2015cites this paper
• Biomarkers of Inflammation in Inflammatory Bowel Disease.

  2015cites this paper
• Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study)

  2015cites this paper
• The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis.

  2014cites this paper
• Comparison of fecal pyruvate kinase isoform M2 and calprotectin in acute diarrhea in hospitalized children

  2014cites this paper
• Epidemiology, demographic characteristics and prognostic predictors of ulcerative colitis.

  2014cites this paper
• The Importance of Mucosal Healing in Ulcerative Colitis

  2014cites this paper
• Role of Fecal Calprotectin in Monitoring Response to Therapy in Inflammatory Bowel Diseases

  2014influential citation
• Fecal calprotectin one year after ileocaecal resection for Crohn's disease--a comparison with findings at ileocolonoscopy.

  2014cites this paper
• Comparison of fecal pyruvate kinase isoform M2 and calprotectin in assessment of pediatric inflammatory bowel disease severity and activity.

  2014cites this paper
• Fecal Calprotectin Assay (Reference ― 2013.03.005) – Notice of Assessment

  2014cites this paper
• Clinical features and diagnosis of ulcerative colitis

  2013cites this paper
• Serum IL-17A in Newly Diagnosed Treatment-Naive Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease

  2013cites this paper